特发性肺纤维化疾病进展保守序列的识别
本研究纳入245例亚临床至晚期家族性肺纤维化(FPF)成人和347例安慰剂治疗的IPF试验患者,用贝叶斯联合重复测量模型描述4项肺功能指标随估计发病年数(EYO)的变化。假定DLCO为70%预计值时发病。FPF中DLCO从EYO -10开始稳步下降,EYO -5达86.8%预计值,EYO +5达45.3%预计值;FVC下降较晚,EYO -5为98.6%,EYO +5为76.2%。EYO +5后一年FVC年化下降6.14%预计值,是EYO -5时0.49%的12倍;EYO每增1年死亡或移植风险HR 1.31(95%CI 1.25-1.37)。RCT中结果相似。
要点
- FPF中DLCO从EYO -10开始下降,EYO +5降至45.3%预计值,而FVC至EYO +5仍为76.2%预计值。
- EYO +5后一年FVC年化下降6.14%预计值,是EYO -5时0.49%预计值的12倍。
- EYO每增加1年,死亡或移植风险HR 1.31(95%CI 1.25-1.37),调整年龄和性别。
- RCT安慰剂组IPF患者中观察到与FPF相似的肺功能下降序列。
- 作者认为该疾病进展模型为研究IPF启动和传播的临床或生物学过程提供了有力框架。
适用人群与场景
- 245例亚临床至晚期家族性肺纤维化(FPF)成人。
- 347例来自2项随机对照试验的安慰剂治疗IPF患者。
诊断标准与关键阈值
- 假定发病时间为DLCO达到70%预计值时。
- 估计发病年数(EYO)以发病时为0,负值代表发病前,正值代表发病后。
研究设计与关键结果
- 研究类型为队列分析,FPF队列245例,RCT安慰剂组347例。
- FPF中DLCO从EYO -10开始稳步下降,EYO -5达86.8%预计值,EYO +5达45.3%预计值。
- FVC下降较晚,EYO -5达98.6%预计值,EYO +5达76.2%预计值。
- EYO +5后一年FVC年化下降6.14%预计值,EYO -5时为0.49%预计值,前者是后者的12倍。
- EYO每增加1年,死亡或移植风险HR 1.31(95%CI 1.25-1.37)。
- RCT中观察到相似结果。
证据类型、等级与局限
- 证据类型:基于2个队列的贝叶斯联合重复测量模型分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该疾病进展模型对临床试验设计有重要意义。
- 作者认为该模型为研究IPF启动和传播的临床或生物学过程提供了有力框架。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Idiopathic pulmonary fibrosis (IPF) begins years before symptoms appear, but the natural history is incompletely understood.
OBJECTIVES: To describe and quantify IPF disease progression using 4 pulmonary function test (PFT) parameters.
METHODS: Two cohorts included 245 adults with subclinical through advanced familial pulmonary fibrosis (FPF) or 347 placebo-treated IPF patients enrolled in 2 randomized controlled trials (RCTs). A Bayesian joint repeated measures model was fit to describe the observed PFT values as a function of the estimated years since onset (EYO). A latent variable estimated the subject-level chronological age at onset. Onset was assumed to occur when the diffusion capacity for carbon monoxide (DLCO) was 70%-predicted. The relationships between EYO and clinical outcomes not included in the model (eg, transplant-free survival) were evaluated, adjusting for age and sex.
MEASUREMENTS AND MAIN RESULTS: In FPF, the DLCO declined steadily starting around EYO -10, reaching 86.8%-predicted by EYO -5 and 45.3%-predicted by EYO +5. The forced vital capacity (FVC) declined later, reaching 98.6%-predicted by EYO -5 and 76.2%-predicted by EYO +5. The annualized decline in FVC was 12-fold greater in the year after EYO +5 (6.14%-predicted) than EYO -5 (0.49%-predicted). There was a 31% higher risk of death or transplant (HR, 1.31 [95% CI, 1.25-1.37]) per 1-year increase in EYO. Similar findings were observed in the RCTs.
CONCLUSIONS: We identified a conserved sequential decline in lung function in IPF, which has important implications for the design of clinical trials. The disease progression model provides a powerful framework to investigate the clinical and/or biological processes that initiate and propagate IPF.
参考来源
- Huang X, Wu P, Guttentag AR, et al. Identification of a conserved sequence of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2026. PMID: 41738263. doi:10.1093/ajrccm/aamag075
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。